EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

EyePoint Pharmaceuticals reports revenue growth and strategic expansion plans

EyePoint Pharmaceuticals showcased strong revenue growth, promising product pipeline with EYP-1901, and strategic partnerships for future expansion. While facing challenges in trial design and molecule size for sustained release, the company is well-positioned for growth with opportunities for collaborations and improved margins in 2023.

EyePoint Pharmaceuticals reports strong Q1 performance and advances revolutionary eye disease treatment

EyePoint Pharmaceuticals (EYPT) delivered a strong Q1 2023 performance, driven by progress in clinical trials for EYP-1901 and a robust YUTIQ franchise.
The company's focus on innovation, safety, and market needs positions EYP-1901 as a potential game-changer in treating chronic eye diseases.
While challenges exist in trial modifications and regulatory considerations, opportunities abound in market expansion, collaboration potential, and regulatory progress.
Overall, EyePoint Pharmaceuticals (EYPT) showcases promising growth prospects and a commitment to advancing novel treatments for retinal diseases.

EyePoint Pharmaceuticals reports Q2 revenue growth amidst operational challenges

EyePoint Pharmaceuticals' Q2 2023 performance showed revenue growth but with significant operating expenses leading to a net loss.
Strengths lie in the progress of EYP-1901, positive data presentations, and a well-capitalized position for future endeavors.
Challenges include financial losses, concerns about patient response variability, and Phase III trial design complexities.
Opportunities exist in exploring funding avenues, post-approval studies, and strategic cost management for Phase III trials.

EyePoint Pharmaceuticals reports Q3 revenue growth and advances drug pipeline

EyePoint Pharmaceuticals showcased progress in drug development and revenue generation in Q3 2023.
The company is strategically positioned with a strong cash position to fund operations into 2025.
Focus on innovative drug delivery mechanisms and collaborations for sustained release treatments.

EyePoint Pharmaceuticals excels in Q4, poised for retinal disease innovation

EyePoint Pharmaceuticals delivered strong financial results, showcased promising trial outcomes for EYP-1901 in wet AMD, and addressed key analyst inquiries regarding market dynamics and competition. With a focus on innovation and strategic leadership appointments, the company is poised for transformative developments in retinal disease treatments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants George Elston - CFO Nancy Lurker - President and CEO Jay Duker - COO Scott Jones - CCO Conference Call Participants Georgi Yordanov - Cowen Yatin Suneja - Guggenheim Securities Jennifer Kim - Cantor Fitzgerald Yale Jen - Laidlaw & Company Yi Chen - H.C. Wainwright Operator Good morning.

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2022 Earnings Call Transcript

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) executed a license agreement with Betta Pharmaceuticals Co Ltd to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau, and Taiwan.  This agreement expands the collaboration between EyePoint and Equinox.

EyePoint, Expands Pact With Betta Pharma For EYP-1901 In China, Posts Deeper Q1 Loss

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -4% and 10.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates

– Presented positive eight-month safety and efficacy data from ongoing DAVIO Phase 1 clinical trial for EYP-1901 in wet age-related macular degeneration (wet AMD) at Angiogenesis, Exudation, and Degeneration 2022; Phase 2 clinical trial expected to initiate in Q3 2022 –

EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments

- Betta Pharmaceuticals to develop and commercialize EYP-1901 in China, Hong Kong, Macau and Taiwan; EyePoint retains all global ophthalmic rights for EYP-1901 elsewhere -

EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwan

WATERTOWN, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 4, 2022 to report its first quarter 2022 financial results and highlight recent corporate developments.

EyePoint Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

WATERTOWN, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference on Thursday, April 28, 2022 at 9:30 am ET.

EyePoint Pharmaceuticals to Participate in Fireside Chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference

New structure replaces existing facility with a significant interest rate reduction resulting in approximately $2.8 million of annualized interest savings New structure replaces existing facility with a significant interest rate reduction resulting in approximately $2.8 million of annualized interest savings

EyePoint Pharmaceuticals Announces Debt Refinancing with $45M Credit Facilities from Silicon Valley Bank

WATERTOWN, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the appointment of Isabelle Lefebvre as Chief Regulatory Officer. Ms. Lefebvre brings over 30 years of global regulatory affairs experience across all phases of drug development including ophthalmic and ocular conditions. Ms. Lefebvre is succeeding John Weet, Ph.D., who be leaving his role as Senior Vice President, Regulatory, following a transition period.

EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officer

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q4 2021 Results - Earnings Call Transcript

– Positive EYP-1901 DAVIO Phase 1 eight-month data was presented at Angiogenesis, Exudation, and Degeneration 2022 virtual meeting on February 12, 2022, continuing positive safety and efficacy profile seen at six-month readout

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Developments

WATERTOWN, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 10:30 a.m. ET.

EyePoint Pharmaceuticals to Participate in Fireside Chat at the Cowen 42nd Annual Health Care Conference

WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and highlight recent corporate developments.

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

WATERTOWN, Mass., Feb. 12, 2022 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced updated interim data from the "Durasert® and Vorolanib in Ophthalmology" (DAVIO) Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting wet age-related macular degeneration (wet AMD).

EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

– Updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD continue to show positive safety and efficacy results out to eight months. Further results to be presented at the February Angiogenesis 2022 virtual meeting –

EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements

WATERTOWN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the appointment of Michael C. Pine as Chief Corporate Development and Strategy Officer. Mr. Pine brings over 20 years of business and corporate development expertise, leveraging experience from various roles at small and large pharmaceutical companies.

EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer

Founded by Renowned Experts in Ophthalmology and Immunology

Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology

ImprimisRx to assume full responsibility for U.S. sales and marketing activities for DEXYCU® and absorb the majority of EyePoint's DEXYCU commercial organization; EyePoint to retain DEXYCU NDA, revenue recognition, manufacturing and distribution responsibilities for all markets ImprimisRx to assume full responsibility for U.S. sales and marketing activities for DEXYCU® and absorb the majority of EyePoint's DEXYCU commercial organization; EyePoint to retain DEXYCU NDA, revenue recognition, manufacturing and distribution responsibilities for all markets

EyePoint Pharmaceuticals and Harrow Health's ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU®

WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 shares of its common stock. The shares of common stock were sold at a public offering price of $13.75 per share, and the pre-funded warrants were sold at a purchase price of $13.74 per pre-funded warrant, for aggregate gross proceeds of approximately $115.4 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. All of the securities were sold by EyePoint.

EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering

The eyecare specialist has good momentum behind it as it prices a new round of capital raising.

Why EyePoint Pharmaceuticals Shot 31% Higher Today

The shares of Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) increased by over 30% during intraday trading today. This is why it happened.

Eyepoint Pharmaceuticals (EYPT) Stock: Why The Price Surged Today

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has priced an underwritten public offering of 4.03 million at $13.75 per share and pre-funded warrants to purchase up to an aggregate of 3.27 million shares at $13.74 per pre-funded warrant. The offer price represents a discount of 5% from the last close price of $14.50 on Tuesday.

EyePoint Pharmaceuticals Raises $100M Via Capital Raise At 5% Discount

WATERTOWN, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the pricing of an underwritten public offering of 4,027,273 shares of its common stock at a public offering price of $13.75 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 3,272,727 shares of its common stock at a price to the public of $13.74 per each pre-funded warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $100.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. In addition, EyePoint has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,095,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock and pre-funded warrants are being sold by EyePoint.

EyePoint Pharmaceuticals Announces Pricing of Public Offering

EyePoint Pharmaceuticals (EYPT) stock is heading higher on Monday thanks to interim results from a Phase 1 clinical trial. The post EYPT Stock: The Clinical Trial News That Has EyePoint Pharma Investors Seeing Green Today appeared first on InvestorPlace.

EYPT Stock: The Clinical Trial News That Has EyePoint Pharma Investors Seeing Green Today

WATERTOWN, Mass., Nov. 13, 2021 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced six-month interim data from the "Durasert® and Vorolanib in Ophthalmology" (DAVIO) Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting wet age-related macular degeneration (wet AMD).

EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

News for EyePoint Pharmaceuticals Stock (EYPT)